

Neurotransmitter Receptor Binding Studies Predict Antiemetic Efficacy and Side Effects^{1,2}

Pamela J. Ison and Stephen J. Peroutka^{3,4,*}

Radioligand binding studies were used to analyze the interaction of antiemetics with central dopamine D₂ and alpha-adrenergic₁ receptors. The affinity of antiemetics for dopamine D₂ receptors labeled by ³H-spiroperone significantly correlated with clinically effective drug doses ($r = 0.92$; $P < 0.01$). Furthermore, the relative inhibition of alpha-adrenergic₁ receptors as measured by ³H-WB 4101 binding predicts the clinical side effects of sedation and orthostatic hypotension. Neurotransmitter receptor binding analysis provides a rapid and sensitive technique for measuring antiemetic potency as well as associated side effects. [Cancer Treat Rep 70:637-641, 1986]

Nausea and vomiting are two of the most untoward side effects of cancer chemotherapy (1-3). To date, a variety of pharmacological agents have been used in the treatment of chemotherapy-induced nausea and vomiting (4-8). In particular, neuroleptics are commonly used therapeutic agents. Theoretically, their efficacy derives from a blockade of dopamine receptors, presumably in the region of the area postrema (9). However, neuroleptics vary in their clinical efficacy and, in addition, are frequently associated with severe side effects such as sedation and orthostatic hypotension.

Radioligand binding studies provide a rapid and sensitive measure of drug potencies at central neurotransmitter receptor binding sites (10,11). For example, the potency of neuroleptics in blocking dopamine D₂ receptors correlates significantly with their antipsychotic activity (12). In addition, drug affinity for alpha-adrenergic₁ receptors has been used as a predictor of clinical sedation and orthostatic hypotension (13,14). We therefore examined a series of ten antiemetics and three neuroleptics at both dopamine D₂ receptors labeled by ³H-spiroperone and alpha-adrenergic₁ receptors labeled by ³H-WB 4101. We now report that radioligand binding studies can be used as a rapid biochemical screen of antiemetic efficacy and side effects.

MATERIALS AND METHODS

Receptor binding assays were performed according to the methods of Peroutka et al (13). Briefly, adult rat brains were purchased from Pel-Freez Biologicals (Rog-

ers, AR) and stored at -20°C. The brains were defrosted and the various anatomical regions were dissected as needed immediately prior to each experiment. Tissues were homogenized in 20 volume of 50 mM Tris-HCl buffer (pH 7.7 at 25°C) using a Brinkmann Polytron and then centrifuged at 49,000 × *g* for 10 minutes. The supernatant was discarded and the pellet resuspended in the same volume of Tris-HCl buffer prior to a second centrifugation at 49,000 × *g* for 10 minutes. The final pellet was resuspended in 80 volume of Tris-HCl buffer for ³H-WB 4101 binding in the cortex or in 240 volume of Tris-HCl buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂, and 1 mM MgCl₂ for ³H-spiroperone binding in the caudate.

Binding assays consisted of 0.1 ml of ³H-ligand (final concentration of 0.5 nM ³H-WB 4101 or 0.8 nM ³H-spiroperone), 0.1 ml of buffer or displacing drug, and 0.8 ml of tissue suspension. This concentration of ³H-WB 4101 was used due to the recent observation of Norman et al (15) that higher concentrations of ³H-WB 4101 (3 nM) also label 5-hydroxytryptamine_{1A} receptors. Following incubation at 25°C for 30 minutes, the assays were rapidly filtered under vacuum through glass fiber filters (Schleicher and Schuell; #32 glass; Keene, NH) with two 5-ml washes using 50 mM Tris-HCl buffer. Radioactivity was measured by liquid scintillation spectroscopy in 7 ml of Aquasol (New England Nuclear; Boston, MA) at 54% efficiency. Specific binding was defined as the excess over blanks taken in the presence of 1 μM droperidol for ³H-WB 4101 binding and 1 μM (+)-butaclamol for ³H-spiroperone binding. Generally, 75%-80% of the total ³H-WB

¹Received June 24, 1985; revised Oct 7, 1985; accepted Oct 11, 1985.

²Supported by the Pimley Research Fund and by NASA grant NCA 2-1R745-504.

³Department of Neurology, Stanford University Medical Center, CA.

⁴We thank Betty Riccio for manuscript preparation.

*Reprint requests to: Dr. Stephen J. Peroutka, Department of Neurology, Stanford University Medical Center, Stanford, CA 94305.

4101 binding and 60%-70% of the total ³H-spiroperone binding was specific.

Drugs were dissolved as follows: amitriptyline, trimethobenzamide, and metoclopramide in 50 mM Tris-HCl buffer; chlorpromazine and trifluoperazine in deionized water; droperidol, haloperidol, thiethylperazine, and fluphenazine were first dissolved in 1-3 ml of 95% ETOH and then diluted in buffer; and (+)-butaclamol, domperidone, pimozide, prochlorperazine, and spiperone were first dissolved in 0.01-1 ml of glacial acetic acid and then diluted in buffer.

Drugs were obtained from the following sources: ³H-WB 4101 and ³H-spiroperone (19.8 Ci/mmol and 23.4 Ci/mmol, respectively; New England Nuclear), amitriptyline, chlorpromazine, and metoclopramide (Sigma Chemical Co, St Louis, MO); droperidol, domperidone, and spiperone (Janssen Pharmaceuticals, Piscataway, NJ); (+)-butaclamol (Research Biochemicals, Inc, Waltham, MA); trifluoperazine and prochlorperazine (Smith, Kline & French, Philadelphia, PA); thiethylperazine (Boehringer Ingelheim Ltd, Ridgefield, CT); and trimethobenzamide (Beecham Laboratories, Bristol, TN).

RESULTS

The affinities of antiemetic drugs for dopamine D₂ receptors in neuronal membranes were determined (table 1). Of the 13 drugs selected for analysis, spiperone and fluphenazine are the most potent agents at the dopamine D₂ receptor with affinities of 0.23 and 0.50 nM, respectively. Thiethylperazine, (+)-butaclamol, haloperidol, and droperidol are essentially equipotent with K_i values of 1-2 nM. Trifluoperazine is slightly less potent at this receptor (K_i = 2.3 nM). By contrast, pimozide, prochlorperazine, and domperidone have affinities of approximately 10 nM. Chlorpromazine (K_i = 21 nM) is approximately one order of magnitude less potent than trifluoperazine. Metoclopramide is significantly less potent at

the dopamine D₂ receptor, with an apparent K_i value of 160 nM. The least potent agent is trimethobenzamide, with a K_i value of 640 nM.

Of the 13 agents analyzed, ten have been previously studied in clinical antiemetic trials. The average recommended clinical dose for each of these ten agents was obtained from the literature (table 1). As shown in figure 1, a significant correlation exists between the average recommended clinical dose and antiemetic potency at the dopamine D₂ receptor ($r = 0.92$; $P < 0.01$).

Antiemetic potency was also assessed at central alpha-adrenergic₁ receptors labeled by ³H-WB 4101. In general, each of these agents also displays high affinity for this neurotransmitter receptor site. As shown in table 2, droperidol (K_i = 1.3 nM) is the most potent agent at the alpha-adrenergic₁ receptor. Drugs such as fluphenazine, haloperidol, spiperone, thiethylperazine, and chlorpromazine all display approximately 10 nM affinity for this receptor. By contrast, (+)-butaclamol, trifluoperazine, pimozide, and domperidone are approximately fivefold to tenfold weaker at the ³H-WB 4101 binding site. Prochlorperazine is significantly less potent than these agents, with a K_i value of 200 nM. Finally, metoclopramide and trimethobenzamide are essentially inactive at the alpha-adrenergic₁ site, with K_i values > 10,000 nM.

A comparison of the relative inhibition of dopamine D₂ and alpha-adrenergic₁ receptors by chlorpromazine and prochlorperazine is shown in figure 2. As shown in figure 2A, prochlorperazine begins to inhibit the binding of ³H-spiroperone at the dopamine D₂ receptor at concentrations > 3 nM. By concentrations > 10 nM, approximately 50% of the specific ³H-spiroperone binding has been displaced by prochlorperazine. At 1000 nM, prochlorperazine completely inhibits the binding of ³H-spiroperone to the dopamine D₂ receptor. By contrast, prochlorperazine is less potent in inhibiting the binding of ³H-WB 4101 to the alpha-adrenergic₁ receptor. No effect on the ³H-WB 4101 binding is observed until concentrations > 100 nM are

TABLE 1.—Antiemetic interactions with dopamine D₂ receptors

Drug	Trade name	Recommended clinical dose (mg)*	Potency at dopamine D ₂ receptor (K _i in nM)
Spiperone	—	—	0.23
Fluphenazine	Prolixin	1.5-2	0.50
Thiethylperazine	Torecan	10-20	1.1
(+)-Butaclamol	—	—	1.3
Haloperidol	Haldol	1-10	1.3
Droperidol	Inapsone	5-10	1.9
Trifluoperazine	Stelazine	1	2.3
Prochlorperazine	Compazine	10-25	6.8
Pimozide	Orap	—	7.8
Domperidone	Motilium	4-20	11
Chlorpromazine	Thorazine	10-300	21
Metoclopramide	Reglan	70-210	160
Trimethobenzamide	Tigan	300-950	640

* Clinical data were obtained from ref Nos. 3, 5, 8, and 19.




FIGURE 1.—Correlation between antiemetic affinity for dopamine D_2 receptors labeled by 3H -spiperone and average recommended clinical doses.

achieved. At a concentration of approximately 500 nM, 50% of the specific alpha-adrenergic₁ binding is displaced. No residual binding remains in the presence of 10,000 nM prochlorperazine.

An inverse pattern of relative drug potency is observed with chlorpromazine (fig 2B). Chlorpromazine is most potent in inhibiting 3H -WB 4101 binding to the alpha-adrenergic₁ receptor, with displacement first noted at 1 nM and becoming maximal at 1000 nM. Inhibition (50%) of alpha-adrenergic₁ receptor binding occurs at approxi-

mately 20 nM. Approximately tenfold higher concentrations of chlorpromazine are needed to achieve the same effect at the dopamine D_2 receptor labeled by 3H -spiperone.

DISCUSSION

The major finding of the present study is that neurotransmitter receptor binding techniques can be used to screen for both the clinical efficacy and potential side effects of antiemetics. These data extend and confirm the observation of Peroutka and Snyder (11) that antiemetics display high affinity for dopamine D_2 , histamine, and/or muscarinic cholinergic receptors. Theoretically, the antiemetic effects of neuroleptics derive from their blockade of dopamine receptors in the chemoreceptor trigger zone (16,17). In particular, dopamine D_2 receptors have been identified in the area postrema (9). These receptors can be directly labeled using 3H -spiperone as a radioligand in neuronal membrane preparations. Since the affinities of antiemetics for these receptors significantly correlate with their effective clinical doses ($r = 0.92$; $P < 0.01$), these data confirm that the dopamine D_2 receptor mediates antiemetic actions.

The ability to predict antiemetic efficacy based on radioligand data has many practical implications. First of all, drugs such as spiperone, pimozide, and (+)-butaclamol are currently unavailable for clinical use in the United States. However, the data in the present study

TABLE 2.—Antiemetic interactions with alpha-adrenergic₁ receptors

Drug	Potency at alpha-adrenergic ₁ receptors (K_1 in nM)	Ratio of K_1 alpha-adrenergic ₁ : K_1 dopamine D_2 *
Chlorpromazine	8.8	0.42
Droperidol	1.3	0.68
Domperidone	74	6.7
Pimozide	78	10
Haloperidol	14	11
Thiethylperazine	17	15
Fluphenazine	8.1	16
Trimethobenzamide	18,000	25
Prochlorperazine	200	29
Trifluoperazine	68	30
(+)-Butaclamol	45	35
Metoclopramide	10,000	62
Spiperone	25	110

* From table 1.




FIGURE 2.—Inhibition of dopamine D₂ receptors labeled by ³H-spiperone and alpha-adrenergic₁ receptors labeled by ³H-WB 4101. A (inhibition by prochlorperazine) and B (inhibition by chlorpromazine).

suggest that these agents should be potent antiemetics. Second, the potency of novel antiemetics at the dopamine D₂ receptor may be a useful predictor of effective doses in pilot clinical trials. Third, radioligand studies may be useful in determining the primary site of drug action. For example, the therapeutic efficacy of metoclopramide has been attributed to its effects on gastric motility (18), while the mechanism of action of trimethobenzamide is unclear (2-8). The current data suggest that dopamine receptor blockade plays a prominent, if not primary, role in the antiemetic effects of these two drugs.

At the same time, the interactions of drugs with alpha-adrenergic₁ receptors have been correlated with sedative and orthostatic hypotensive side effects (13,14). These side effects have also been noted with antiemetics. Clinical studies have shown that the incidence of orthostatic hypotension and sedation varies widely among antiemetics. For example, chlorpromazine and prochlorperazine are essentially equipotent antiemetics. However, the incidence of sedative and orthostatic side effects with chlorpromazine is far more frequent and severe than that observed with prochlorperazine (8,19).

The use of ³H-WB 4101 to label the alpha-adrenergic₁ receptors appears to be a useful tool for the analysis of these effects. The relative potencies of drugs at alpha-adrenergic₁ and dopamine D₂ receptors may explain the variability of the side effects. For example, chlorpromazine is more than twice as potent at alpha-adrenergic₁ receptors than at dopamine D₂ receptors. At clinically effective antiemetic doses, dopamine D₂ receptors are theoretically blocked by chlorpromazine. At such concentra-

tions, an even greater percentage of alpha-adrenergic₁ receptors are simultaneously blocked. By contrast, at concentrations of prochlorperazine at which a significant proportion of dopamine D₂ receptors are blocked (10 nM), only a small percentage of alpha-adrenergic₁ sites are blocked. Thus, the ratio of alpha-adrenergic₁ to dopamine D₂ affinities can be used as a measure of sedation and orthostatic hypotension. Based on these data, chlorpromazine and droperidol should be relatively sedative, whereas trifluoperazine and metoclopramide should be less sedating. These predictions have been confirmed by clinical experience (8,19-21).

Therefore, radioligand binding studies may provide a useful and accurate laboratory predictor of clinical antiemetic efficacy. In particular, binding studies could be used as a screening device for novel antiemetics that act through dopamine D₂ receptors. These techniques may also be applied to the study of antiemetics which act at histamine and muscarinic cholinergic receptors. The experiments could be performed rapidly and economically. Moreover, receptor binding studies can also be used to predict major side effects. Finally, the use of receptor binding assays in the analysis of antiemetic action may provide important information concerning the pathophysiology of nausea and vomiting in humans.

REFERENCES

1. MORRAN C, SMITH DC, ANDERSON DA, ET AL. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. *Br Med J* 1:1323-1324, 1979.

2. LASZLO J. Nausea and vomiting as major complications of cancer chemotherapy. *Drugs* 25 (suppl 1):1-7, 1983.
3. FHYTAK S, and MOERTEL CG. Management of nausea and vomiting in the cancer patient. *JAMA* 245:393-396, 1981.
4. SEIGEL LJ, and LONGO DL. The control of chemotherapy-induced emesis. *Ann Intern Med* 95:352-359, 1981.
5. WOOD CD. Antimotion sickness and antiemetic drugs. *Drugs* 17:471-479, 1979.
6. LASZLO J. Treatment of nausea and vomiting caused by cancer chemotherapy. *Cancer Treat Rev* 9 (suppl B):3-9, 1982.
7. PENTA J, PORTER D, and BRUNO S. The pharmacologic treatment of nausea and vomiting caused by cancer chemotherapy: a review. *In* *Antiemetics and Cancer Chemotherapy* (Laszlo J, ed). Baltimore, Williams and Wilkins, 1983, pp 53-92.
8. NEIDHART JA, and COGAN M. Experimental antiemetic agents (other than the cannabinoids and metoclopramide). *In* *Antiemetics and Cancer Chemotherapy* (Laszlo J, ed). Baltimore, Williams and Wilkins, 1983, pp 142-163.
9. STEFANINI E, and CLEMENT-CORMIER Y. Detection of dopamine receptors in the area postrema. *Eur J Pharmacol* 74:257-260, 1981.
10. SNYDER SH. Drugs and neurotransmitter receptors in the brain. *Science* 224:22-31, 1983.
11. PEROUTKA SJ, and SNYDER SH. Antiemetics: neurotransmitter binding predicts therapeutic actions. *Lancet* 2:658-659, 1982.
12. CREESE I, BURT DR, and SNYDER SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. *Science* 192:481-483, 1976.
13. PEROUTKA SJ, UPRICHARD DC, GREENBERG DA, ET AL. Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. *Neuropharmacology* 16:549-556, 1977.
14. UPRICHARD DC, GREENBERG DA, SHEEHAN PP, ET AL. Tricyclic antidepressants: therapeutic properties and affinity for alpha-norenergic receptor binding sites in the brain. *Science* 199:197-199, 1978.
15. NORMAN AB, BATTAGLIA G, MORROW AL, ET AL. ³H-WB-4101 labels S₁ serotonin receptors in rat cerebral cortex. *Eur J Pharmacol* 106:461-462, 1985.
16. BORISON HL, and WANG SC. Physiology and pharmacology of vomiting. *Pharmacol Rev* 5:193-230, 1953.
17. BORISON HL, and MCCARTHY LE. Neuropharmacology of chemotherapy-induced emesis. *Drugs* 25 (suppl 1):8-17, 1983.
18. SCHULZE-DELRIEU K. Metoclopramide. *N Engl J Med* 305:28-33, 1981.
19. BYCK R. Drugs and the treatment of psychiatric disorders. *In* *The Pharmacological Basis of Therapeutics* (Goodman LS, and Gilman A, eds). New York, Macmillan, 1975, pp 170-171.
20. LUCAS VS. Phenothiazines as antiemetics. *In* *Antiemetics and Cancer Chemotherapy* (Laszlo J, ed). Baltimore, Williams and Wilkins, 1983, pp 93-107.
21. GRALLA RJ, TYSON LB, BORDIN LA, ET AL. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. *Cancer Treat Rep* 68:163-172, 1984.